In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of goods and services tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.53638% increase.
Sl No | Medicines | Dosage form and Strength | Unit | Ceiling price (wef 01.04.2021 with WPI @ 0.53638%) | Existing S.O. No. & Date |
(1) | (2) | (3) | (4) | (5) | 6(a) | 6(b) |
1 | Acetyl Salicylic Acid | Tablet 300mg | 1 Tablet | 0.22687
| 1214 (E) | 25.03.2020 |
2 | Calcium carbonate | Tablet 250 mg | 1 Tablet | 1.96 | 1214 (E) | 25.03.2020 |
3 | Condoms | | 1 Condom | 9.15
| 1214 (E) | 25.03.2020 |
4 | Dapsone | Tablet 50 mg | 1 Tablet | 0.23656 | 1214 (E) | 25.03.2020 |
5 | Etoposide | Capsules 100 mg | 1 Capsule | 60.69
| 1214 (E) | 25.03.2020 |
6 | Framycetin Sulphate | Cream 0.50% | 1 GM | 0.87467
| 1214 (E) | 25.03.2020 |
7 | Isoniazid | Syrup 100 mg/5ml | 1 ML | 0.2591 | 1214 (E) | 25.03.2020 |
8 | Medroxy Progesterone Acetate | Tablet 5mg | 1 Tablet | 3.00
| 1214 (E) | 25.03.2020 |
9 | Rifampicin | Tablet 450mg | 1 Tablet | 4.44 | 1214 (E) | 25.03.2020 |
The notification further added;
(a) The ceiling prices are applicable with effect from 01.04.2021 (ceiling prices are inclusive of Wholesale Price Index (WPI) @0.53638% for the year 2020 over 2019).
(b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services taxes as applicable if any.
(c) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.53638% for the year 2020 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.
(d) The manufacturers may add goods and services taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(e) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(f) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(g) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(h) The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(i) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(j) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
To view the official notice, click on the following link:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.